Literature DB >> 7519079

Generation of human natural killer cells from immature progenitors does not require marrow stromal cells.

M R Silva1, R Hoffman, E F Srour, J L Ascensao.   

Abstract

Human natural killer (NK) cells comprise 10% to 15% of peripheral blood mononuclear cells and have an important role in immune responses against tumors, viral infections, and graft rejection. NK cells originate in bone marrow (BM), but their progenitors and lineage development have not been completely characterized. We studied the generation of NK cells from purified CD34+HLADR- and CD34+HLADR+ BM progenitors and the influence of various cytokines on their production. We show that CD3-CD56+ cytotoxic NK cells can develop from both progenitors populations when interleukin-2 (IL-2) is present in an in vitro suspension culture system containing IL-1 alpha and stem cell factor. Up to 83.8% and 98.6% CD3-CD56+ cells were detected in CD34+HLADR- and CD34+DR+ cultures, respectively, after 5 weeks of culture; significant numbers of NK cells were first detected after 2 weeks. Cytotoxic activity paralleled NK cell numbers; up to 70% specific lysis at an effector:target ratio of 10:1 was observed at 5 weeks. IL-7 also triggered development of CD3-CD56+ cells from these immature progenitors (up to 24% and 55% appeared in CD34+HLADR- and CD34+HLADR+ cultures, respectively). Our data suggest that BM stromas are not necessary for NK cell development and that IL-2 remains essential for this lineage development and differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519079

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Authors:  T A Fehniger; E M Bluman; M M Porter; E Mrózek; M A Cooper; J B VanDeusen; S R Frankel; W Stock; M A Caligiuri
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children.

Authors:  Matthias M Pfeiffer; Tobias Feuchtinger; Heiko-Manuel Teltschik; Michael Schumm; Ingo Müller; Rupert Handgretinger; Peter Lang
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

3.  Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.

Authors:  Valarie McCullar; Robert Oostendorp; Angela Panoskaltsis-Mortari; Gong Yun; Charles T Lutz; John E Wagner; Jeffrey S Miller
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

4.  Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation.

Authors:  Simona Sivori; Michela Falco; Emanuela Marcenaro; Silvia Parolini; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

5.  Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.

Authors:  I M Bennett; O Zatsepina; L Zamai; L Azzoni; T Mikheeva; B Perussia
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

6.  Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates.

Authors:  N S Williams; T A Moore; J D Schatzle; I J Puzanov; P V Sivakumar; A Zlotnik; M Bennett; V Kumar
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

7.  CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines.

Authors:  Giuseppe Sconocchia; Maurizio Provenzano; Katayoun Rezvani; Jongming Li; Jos Melenhorst; Nancy Hensel; A John Barrett
Journal:  J Transl Med       Date:  2005-04-14       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.